Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.
Also called NCT07695701
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Registry
-
NCT07695701 -
2026-526068-19-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07695701. Allocation not applicable; no masking; primary purpose treatment. Start 2026-07 (anticipated); primary completion 2030-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
- Acronym
- ASCEND-ATTR
- Condition
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
- Condition
- Amyloidosis
- Condition
- Amyloid Cardiomyopathy
- Condition
- Transthyretin Amyloidosis
- Intervention (Drug)
- Acoramidis (AG10) oral tablet
- Lead sponsor
- Eidos Therapeutics, a BridgeBio company
Record details
- Record id
cardio:ct-nct07695701- Content hash
e43f4a5a9ecf422f3e124940319a42190e2025626fb17261eebe110baa04ac0c